AGA临床实践更新:慢性丙型肝炎口服直接抗病毒药物与肝细胞癌相互作用的专家综述
本AGA临床实践更新评估直接抗病毒药物(DAA)治疗与肝细胞癌(HCC)发生、复发及DAA疗效之间的相互作用,基于已发表观察性研究和系统综述并纳入专家意见,汇总关于HCC监测和DAA治疗时机的最佳实践建议。
要点
- DAA治疗与HCC发生风险降低相关,肝硬化和无肝硬化患者的相对风险降低相似。
- 晚期肝纤维化(F3)或肝硬化患者应在DAA治疗前接受监测影像,并在DAA诱导持续病毒学应答后继续HCC监测。
- HCC监测应每6个月一次采用超声联合或不联合甲胎蛋白,当前数据不支持缩短间隔或替代监测方式。
核心结论
- DAA治疗与HCC发生风险降低相关,肝硬化和无肝硬化患者的相对风险降低相似。
- 活动性HCC与DAA治疗持续病毒学应答小幅但具有统计学意义的降低相关。
- 对HCC治疗完全应答的患者接受DAA治疗仍有HCC复发风险,需无限期监测。
研究设计与样本
- 本临床实践更新由AGA研究所制作,建议基于已发表的观察性研究和系统综述,并在适用处纳入专家意见。
主要发现
- DAA治疗与HCC发生风险降低相关,肝硬化和无肝硬化患者的相对风险降低相似。
- 活动性HCC与DAA治疗持续病毒学应答小幅但具有统计学意义的降低相关。
- 无 conclusive 数据表明DAA治疗与HCC治疗完全应答患者的复发风险增加或降低、复发时间差异或复发HCC侵袭性相关。
关键数值与推荐
- 最佳实践建议1:DAA治疗与HCC发生风险降低相关,肝硬化和无肝硬化患者的相对风险降低相似。
- 最佳实践建议2:晚期肝纤维化(F3)或肝硬化患者应在开始DAA治疗前接受监测影像。
- 最佳实践建议3:DAA治疗时存在晚期肝纤维化(F3)或肝硬化的患者是DAA诱导持续病毒学应答后HCC最高风险组,应继续HCC监测。
- 最佳实践建议4:HCC监测应每6个月一次采用超声联合或不联合甲胎蛋白;当前数据不支持缩短监测间隔或使用替代监测方式。
- 最佳实践建议5:未来研究可能显示DAA诱导持续病毒学应答后HCC风险随时间降低;但在此期间,如果患者其他方面符合潜在治愈性治疗条件,应无限期继续HCC监测。
临床怎么用
- DAA治疗与HCC发生风险降低相关,肝硬化和无肝硬化患者的相对风险降低相似。
- 晚期肝纤维化(F3)或肝硬化患者应在开始DAA治疗前接受监测影像,并在DAA诱导持续病毒学应答后继续HCC监测。
- HCC监测应每6个月一次采用超声联合或不联合甲胎蛋白,当前数据不支持缩短间隔或替代监测方式。
- 符合肝切除或消融潜在治愈性治疗条件的HCC患者应推迟DAA治疗直至HCC治疗完成。
- 不应拒绝给予HCC治疗完全应答患者DAA治疗;但DAA治疗可推迟4-6个月以确认对HCC治疗的应答。
局限性
- 评估DAA治疗在活动性中晚期HCC患者中的获益和成本效益的数据不足。
- 无 conclusive 数据表明DAA治疗与HCC治疗完全应答患者的复发风险增加或降低、复发时间差异或复发HCC侵袭性相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: The purpose of this clinical practice update is to evaluate the evidence describing the interaction between direct-acting antiviral (DAA) therapy for hepatitis and hepatocellular carcinoma (HCC) with regard to HCC incidence, HCC recurrence, and DAA efficacy, and to summarize best practice advice regarding HCC surveillance and timing of DAA therapy. METHODS: The recommendations outlined in this expert review are based on available published evidence, including observational studies and systematic reviews, and incorporates expert opinion where applicable. BEST PRACTICE ADVICE 1: DAA treatment is associated with a reduction in the risk of incident HCC. The relative risk reduction is similar in patients with and without cirrhosis. BEST PRACTICE ADVICE 2: Patients with advanced liver fibrosis (F3) or cirrhosis should receive surveillance imaging before initiating DAA treatment. BEST PRACTICE ADVICE 3: Patients with advanced liver fibrosis (F3) or cirrhosis at the time of DAA treatment represent the highest-risk group for HCC after DAA-induced sustained virologic response. These patients should stay in HCC surveillance. BEST PRACTICE ADVICE 4: HCC surveillance should be performed using ultrasound with or without α-fetoprotein every 6 months. Current data do not support shorter surveillance intervals or the use of alternative surveillance modalities. BEST PRACTICE ADVICE 5: Future studies may show a reduction in HCC risk over time after DAA-induced sustained virologic response. However, in the interim, HCC surveillance should continue indefinitely if patients are otherwise eligible for potentially curative therapy. BEST PRACTICE ADVICE 6: The presence of active HCC is associated with a small but statistically significant decrease in sustained virologic response with DAA therapy. BEST PRACTICE ADVICE 7: Patients with HCC who are eligible for potentially curative therapy with liver resection or ablation should defer DAA therapy until after HCC treatment is completed. BEST PRACTICE ADVICE 8: Timing of DAA therapy for patients with HCC who are listed for liver transplantation should be determined with consideration of median wait times, availability of hepatitis C virus-positive organs, and degree of liver dysfunction. BEST PRACTICE ADVICE 9: There are insufficient data evaluating benefits and cost-effectiveness of DAA therapy in patients with active intermediate or advanced HCC. Decisions regarding DAA treatment in these patients should be considered in light of HCC tumor burden, degree of liver dysfunction, life expectancy, and patient preferences. BEST PRACTICE ADVICE 10: There are no conclusive data that DAA therapy is associated with increased or decreased risk, differential time to recurrence, or aggressiveness of recurrent HCC in patients with complete response to HCC therapy. BEST PRACTICE ADVICE 11: DAA therapy should not be withheld from patients with complete response to HCC therapy; however, DAA therapy can be deferred 4-6 months to confirm response to HCC therapy. BEST PRACTICE ADVICE 12: Patients with complete response to HCC therapy who are treated with DAAs have a continued risk of HCC recurrence and require HCC surveillance, which should be conducted indefinitely with dynamic contrast-enhanced computed tomography or magnetic resonance imaging every 3-6 months. Current data do not support more frequent surveillance in these patients. This Clinical Practice Update was produced by the AGA Institute.
引用
- Singal AG, Lim JK, Kanwal F, et al. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Gastroenterology. 2019. PMID: 30878469. doi:10.1053/j.gastro.2019.02.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。